ストックスクリーナーアプリを入手
2.73
6.83%
-0.20
プレマーケット:
2.88
0.15
+5.49%
前日終値:
$2.93
開ける：
$2.99
24時間の取引高:
606.16K
Relative Volume:
0.12
時価総額：
$36.93M
収益：
$2.09M
当期純損益:
$-30.04M
株価収益率:
-0.8352
EPS:
-3.2685
ネットキャッシュフロー:
$-27.57M
1週間 パフォーマンス:
-4.88%
1か月 パフォーマンス:
-11.36%
6か月 パフォーマンス:
-42.16%
1年 パフォーマンス:
-73.21%
1日の値動き範囲:
$2.68
$2.99
1週間の範囲:
$2.66
$3.20
52週間の値動き範囲:
$2.13
$11.25
Cervomed Inc Stock (CRVO) Company Profile
Compare CRVO vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
2.73 | 41.53M | 2.09M | -30.04M | -27.57M | -3.2685 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-13 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-12-05 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-18 | 開始されました | Chardan Capital Markets | Buy |
| 2024-07-26 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-15 | 開始されました | Canaccord Genuity | Buy |
| 2020-11-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cervomed Inc (CRVO) 最新ニュース
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Stocktwits
CervoMed (CRVO): RA Capital discloses 8.6% stake through 1.27M warrant shares - Stock Titan
CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing - Stock Titan
Woodline Partners (CRVO) discloses 5.1% beneficial stake in CervoMed common stock - Stock Titan
Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund - Stock Titan
CRVO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $18 - Moomoo
CervoMed at Canaccord Genuity conference: dLB push gains ground By Investing.com - Investing.com Canada
CRVO: Phase III-ready DLB drug shows strong clinical data; pipeline expands into PPA and ALS - TradingView
JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
CervoMed reports Q2 2026: $24.9M cash position, net loss $6.6M; advancing neflamapimod toward Phase 3 - TradingView
CervoMed (NASDAQ: CRVO) details Q2 2026 loss, cash runway and DLB program - Stock Titan
Canaccord cuts CervoMed stock price target on funding uncertainty By Investing.com - Investing.com India
CRVO Maintained by Canaccord Genuity -- Price Target Lowered to $18 - GuruFocus
CervoMed Q2 Results: EPS Misses Estimate, Losses Widen YoY - scanx.trade
CervoMed Q2 Results: Net Loss Widens To $6.6M, Seeks DLB Partner - scanx.trade
Canaccord cuts CervoMed stock price target on funding uncertainty - Investing.com
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
CervoMed Q2 net loss lower than estimates as costs drop - TradingView
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $18 - Moomoo
CRVO Q2'26 Earnings: revenue estimate is 50.00K USD - TradingView
CERVOMED INC : CANACCORD GENUITY CUTS TARGET PRICE TO $18 FROM $27 - Bitget
CervoMed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CervoMed Inc. 2026: Revenue $0 Net income ($6.57M), EPS ($0.64) — 10-Q Summary - TradingView
CRVO: Raised $20.5M in June 2026 to fund R&D and strategic partnership for Phase 3 DLB trial - TradingView
CervoMed (NASDAQ: CRVO) raises $20.5M, ends Q2 with $24.9M cash - Stock Titan
CRVO: Neflamapimod progresses to Phase 3 for DLB, with strong cash position and key milestones ahead - TradingView
CervoMed Inc (CRVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CervoMed Inc. (CRVO) Edges Lower to $2.77 as Shares Consolidate Within Tight Trading RangeADD Alert - dars.gov.et
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - manilatimes.net
CervoMed to discuss neflamapimod progress at Ca... - Pluang
CervoMed Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
CervoMed granted UK Innovation Passport for neflamapimod in dementia with Lewy bodies - TradingView
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) - The Manila Times
CervoMed's neflamapimod wins UK ILAP Innovation Passport for DLB - scanx.trade
CervoMed Inc (CRVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CervoMed Inc (CRVO) Cash Flow - TradingKey
CervoMed Inc (CRVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CervoMed Inc (CRVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRVO|CervoMed Inc|Price:2.690|Chg%:+0.030 - TradingKey
CRVO|CervoMed Inc|Price:2.640|Chg%:-0.020 - TradingKey
CervoMed Inc (CRVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CervoMed Inc (CRVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
CervoMed Inc (CRVO) Institutional Confidence - TradingKey
CervoMed Inc (CRVO) Income Statement - TradingKey
CervoMed Inc. Revenue Breakdown – NASDAQ:CRVO - TradingView
CRVO|CervoMed Inc|Price:2.660|Chg%:-0.010 - TradingKey
CervoMed Inc. (CRVO) Q1 2026 Earnings: EPS Misses Estimates as Clinical Investment ContinuesEarnings Acceleration Picks - dars.gov.et
Matt Winton Says Most Biotechs Are Not the Best to Launch Their Own Drugs — and That’s a Strength, Not a Failure - finance.biggo.com
Insiders the Biggest Winners as CervoMed Inc.'s (NASDAQ:CRVO) Market Cap Rises to US$151m - 富途牛牛
H.C. Wainwright reiterates CervoMed stock rating at buy, $25 target - Investing.com UK
Cervomed Inc (CRVO) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):